open access

Vol 8, No 1 (2012)
Review paper
Published online: 2012-03-29
Get Citation

Diffuse large B-cell lymphoma in elderly

Tomasz Wróbel
Onkol. Prak. Klin 2012;8(1):36-40.

open access

Vol 8, No 1 (2012)
REVIEW ARTICLES
Published online: 2012-03-29

Abstract

Approximately 30% of patients with diffuse large B-cell lymphoma (DLBCL) are older than 70 years. Rituximab
added to CHOP remains standard protocol in elderly patients except for those with severe comorbidities.
Treatment with R-CHOP in elderly is complicated by substantial myelotoxicity and doxorubicin
induced cardiotoxicity. Therefore supportive care including granulocytes growth factors administration is
mandatory. This article summarizes possibilities of optimization of therapy of DLBCL in elderly.

Abstract

Approximately 30% of patients with diffuse large B-cell lymphoma (DLBCL) are older than 70 years. Rituximab
added to CHOP remains standard protocol in elderly patients except for those with severe comorbidities.
Treatment with R-CHOP in elderly is complicated by substantial myelotoxicity and doxorubicin
induced cardiotoxicity. Therefore supportive care including granulocytes growth factors administration is
mandatory. This article summarizes possibilities of optimization of therapy of DLBCL in elderly.
Get Citation

Keywords

diffuse large B-cell lymphoma, therapy, elderly

About this article
Title

Diffuse large B-cell lymphoma in elderly

Journal

Oncology in Clinical Practice

Issue

Vol 8, No 1 (2012)

Article type

Review paper

Pages

36-40

Published online

2012-03-29

Bibliographic record

Onkol. Prak. Klin 2012;8(1):36-40.

Keywords

diffuse large B-cell lymphoma
therapy
elderly

Authors

Tomasz Wróbel

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Wydawcą serwisu jest  "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl